Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage
Brief Summary: Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation (OAC) result in a beneficial net reduction of all serious vascular events compared with not starting OAC?

Trial design: Investigator-led, multicentre, randomised, open, assessor-masked, parallel group, clinical trial of investigational medicinal product (CTIMP) prescribing strategies. Investigators plan for a pilot phase, followed by a safety phase.


Options:
A: Arm Label: Antithrombotic treatment; Type: EXPERIMENTAL; Interventions: Drug: Antithrombotic Agent | Arm Label: No antithrombotic treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Antithrombotic Agent; Assigned to Arm(s): Antithrombotic treatment
B: Arm Label: Start oral anticoagulant (OAC); Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Drug: Rivaroxaban, Drug: Edoxaban, Drug: Dabigatran, Drug: Acenocoumarol, Drug: Phenindione, Drug: Warfarin | Arm Label: Do not start oral anticoagulant (OAC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Edoxaban; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Acenocoumarol; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Phenindione; Assigned to Arm(s): Start oral anticoagulant (OAC) | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Start oral anticoagulant (OAC)
C: Arm Label: Direct Oral Anticoagulant; Type: EXPERIMENTAL; Interventions: Drug: Apixaban Oral Tablet, Drug: Dabigatran, Drug: Edoxaban Tablets, Drug: Rivaroxaban | Arm Label: No Anticoagulant; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Apixaban Oral Tablet; Assigned to Arm(s): Direct Oral Anticoagulant | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Direct Oral Anticoagulant | Intervention Type: DRUG; Name: Edoxaban Tablets; Assigned to Arm(s): Direct Oral Anticoagulant | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Direct Oral Anticoagulant
D: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Avoiding oral anticoagulants; Type: OTHER; Interventions: Drug: Aspirin, Drug: Carbasalate calcium, Drug: Clopidogrel, Drug: Dipyridamole, Other: No antithrombotic treatment | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Carbasalate calcium; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: DRUG; Name: Dipyridamole; Assigned to Arm(s): Avoiding oral anticoagulants | Intervention Type: OTHER; Name: No antithrombotic treatment; Assigned to Arm(s): Avoiding oral anticoagulants

Answer: B